Methotrexate Orion (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate, a cofactor needed for DNA synthesis. By limiting nucleotide formation, it slows the growth of rapidly dividing cells and also suppresses inflammatory cytokine production, providing both anti‑cancer and immunosuppressive effects.

The specific dose and schedule of Methotrexate Orion are determined by the prescribing clinician based on the patient’s condition, weight, renal function and treatment goals. Healthcare providers tailor the regimen to achieve therapeutic benefit while minimizing potential toxicity.

Methotrexate Orion is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding because it can be excreted in milk and may harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Methotrexate is a folate antagonist, similar to drugs like pemetrexed, but it is more widely used across both rheumatologic and oncologic indications. Compared with newer targeted agents, methotrexate is less expensive and has a well‑characterized safety profile, though it requires careful monitoring for hepatic and hematologic toxicity.

Methotrexate Orion should be stored at 2‑8 °C in a refrigerator. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Maintaining the cold chain preserves drug stability and potency.

Methotrexate Orion is supplied for parenteral use and can be given either intramuscularly or subcutaneously by a qualified healthcare professional. The injection site is selected based on patient tolerance and clinical guidelines, and the volume is typically small, allowing for convenient administration.

The most serious risks include severe liver injury, pulmonary fibrosis, profound bone‑marrow suppression leading to pancytopenia, and acute kidney failure. Patients should be monitored regularly for liver enzymes, blood counts and renal function, and any signs of infection or respiratory distress should prompt immediate medical evaluation.

Methotrexate Orion is contraindicated in pregnant women, breastfeeding mothers, patients with severe renal or hepatic impairment, and those with known hypersensitivity to methotrexate or its excipients. It should also be avoided in individuals receiving live vaccines due to the risk of severe infection.